Longitudinal Changes of Circulating miRNAs during Bisphosphonate and Teriparatide Treatment in an Animal Model of Postmenopausal Osteoporosis

Objective To evaluate the effect of teriparatide on life quality in patients with postmenopausal osteoporosis. Methods Patients treated from January 2014 to December 2016 were retrospectively included. Patients were divided into two groups according the treatment received. Those in the teriparatide treatment group were followed up for 24 months, and patients in the control group received calcium supplements and vitamin D. Scores for back pain using a visual analog scale (VAS) and score of the Oswestry Disability Index (ODI) and 36-item Short Form Health Survey of life quality (SF-36) were evaluated at 3, 6, 12, and 24 months and compared between the groups. Results In total, 126 patients were included in the teriparatide treatment group and 127 in the control group. There were no significant differences between the groups concerning body mass index, bone density, VAS back pain score, ODI, and SF-36 life quality scores at baseline. At 3, 6, 12, and 24 months’ follow-up, VAS scores were significantly lower in the treatment group than in controls; ODI and SF-36 scores were significantly higher in the treatment group than in the control group. Conclusion Teriparatide can significantly decrease pain and increase mobility and life quality in patients with postmenopausal osteoporosis.

Download Full-text

Switching to denosumab or bisphosphonates after completion of teriparatide treatment in women with severe postmenopausal osteoporosis

Endocrine Practice ◽

10.1016/j.eprac.2021.05.012 ◽

2021 ◽

Author(s):

Tomaz Kocjan ◽

Antonela Sabati Rajic ◽

Andrej Janez ◽

Gaj Vidmar ◽

Nina Orehek ◽

...

Keyword(s):

Postmenopausal Osteoporosis ◽

Teriparatide Treatment

Download Full-text

Teriparatide increases the insertional torque of pedicle screws during fusion surgery in patients with postmenopausal osteoporosis

Journal of Neurosurgery Spine ◽

10.3171/2014.5.spine13656 ◽

2014 ◽

Vol 21 (3) ◽

pp. 425-431 ◽

Cited By ~ 34

Author(s):

Gen Inoue ◽

Masaki Ueno ◽

Toshiyuki Nakazawa ◽

Takayuki Imura ◽

Wataru Saito ◽

...

Keyword(s):

Postmenopausal Women ◽

Postmenopausal Osteoporosis ◽

Pedicle Screws ◽

Treated Group ◽

Control Group ◽

Fusion Surgery ◽

Teriparatide Treatment ◽

Significant Difference ◽

Insertional Torque ◽

The Mean

Object The object of this study was to examine the efficacy of preoperative teriparatide treatment for increasing the insertional torque of pedicle screws during fusion surgery in postmenopausal women with osteoporosis. Methods Fusion surgery for the thoracic and/or lumbar spine was performed in 29 postmenopausal women with osteoporosis aged 65–82 years (mean 72.2 years). The patients were divided into 2 groups based on whether they were treated with teriparatide (n = 13) or not (n = 16) before the surgery. In the teriparatide-treated group, patients received preoperative teriparatide therapy as either a daily (20 μg/day, n = 7) or a weekly (56.5 μg/week, n = 6) injection for a mean of 61.4 days and a minimum of 31 days. During surgery, the insertional torque was measured in 212 screws inserted from T-7 to L-5 and compared between the 2 groups. The correlation between the insertional torque and the duration of preoperative teriparatide treatment was also investigated. Results The mean insertional torque value in the teriparatide group was 1.28 ± 0.42 Nm, which was significantly higher than in the control group (1.08 ± 0.52 Nm, p < 0.01). There was no significant difference between the daily and the weekly teriparatide groups with respect to mean insertional torque value (1.34 ± 0.50 Nm and 1.18 ± 0.43 Nm, respectively, p = 0.07). There was negligible correlation between insertional torque and duration of preoperative teriparatide treatment (r2 = 0.05, p < 0.01). Conclusions Teriparatide injections beginning at least 1 month prior to surgery were effective in increasing the insertional torque of pedicle screws during surgery in patients with postmenopausal osteoporosis. Preoperative teriparatide treatment might be an option for maximizing the purchase of the pedicle screws to the bone at the time of fusion surgery.

Download Full-text

Outcomes of Treatment in Patients with Severe Postmenopausal Osteoporosis: The Effects of Teriparatide Treatment on Bone Mineral Density, Back Pain and Biochemical Parameters

Turkish Journal of Osteoporosis ◽

10.4274/tod.galenos.2019.92668 ◽

2020 ◽

Vol 26 (1) ◽

pp. 6-9

Author(s):

Tuba Nazlıgül ◽

İlknur Aktaş ◽

Feyza Ünlü Özkan ◽

Pınar Akpınar

Keyword(s):

Bone Mineral Density ◽

Back Pain ◽

Postmenopausal Osteoporosis ◽

Bone Mineral ◽

Biochemical Parameters ◽

Mineral Density ◽

Teriparatide Treatment

Download Full-text

Does Discontinuing Teriparatide Treatment and Replacing It with Bisphosphonate Maintain the Volume of the Bone Fusion Mass after Lumbar Posterolateral Fusion in Women with Postmenopausal Osteoporosis?

Asian Spine Journal ◽

10.4184/asj.2017.11.2.272 ◽

2017 ◽

Vol 11 (2) ◽

pp. 272-277 ◽

Cited By ~ 9

Author(s):

Seiji Ohtori ◽

Sumihisa Orita ◽

Kazuyo Yamauchi ◽

Yawara Eguchi ◽

Yasuchika Aoki ◽

...

Keyword(s):

Postmenopausal Osteoporosis ◽

Degenerative Spondylolisthesis ◽

Case Series ◽

Posterolateral Fusion ◽

Retrospective Case ◽

Bone Fusion ◽

Teriparatide Treatment ◽

The Right ◽

Mass Volume ◽

Lumbar Posterolateral Fusion

<sec><title>Study Design</title>Retrospective case series.</sec><sec><title>Purpose</title>The purpose of this study was to determine whether discontinuing teriparatide treatment and replacing it with bisphosphonate treatment maintains the volume of the fusion mass after posterolateral fusion (PLF) in women with postmenopausal osteoporosis.</sec><sec><title>Overview of Literature</title>Clinical data support the efficacy of parathyroid hormone (PTH) for lumbar PLF. However, the use of PTH is limited to 2 years.</sec><sec><title>Methods</title>We treated 19 women diagnosed with osteoporosis and degenerative spondylolisthesis with teriparatide (20 µg daily subcutaneously). All patients underwent one-level instrumented PLF. Teriparatide was used during 2 months prior to surgery and more than 8 months after surgery. After discontinuing teriparatide treatment, all patients used bisphosphonate (17.5 mg risedronate weekly, oral administration). Area of the fusion mass across the transverse processes at one segment was determined on an anteroposterior radiograph at 1, 2, and 3 years after surgery.</sec><sec><title>Results</title>We followed 19 patients for 3 years. The average duration of teriparatide treatment was 11.5 months. The bone union rate was 95%. The average area of the bone fusion mass was not significantly different between the right and left sides at 1, 2, or 3 years after surgery (<italic>p</italic>>0.05).</sec><sec><title>Conclusions</title>This study showed that replacing teriparatide treatment with bisphosphonate maintained the bone fusion mass volume after PLF in women with postmenopausal osteoporosis.</sec>

Download Full-text

MicroRNA levels in bone and blood change during bisphosphonate and teriparatide therapy in an animal model of postmenopausal osteoporosis

10.1101/591990 ◽

2019 ◽

Author(s):

Roland Kocijan ◽

Moritz Weigl ◽

Susanna Skalicky ◽

Elisabeth Geiger ◽

James Ferguson ◽

...

Keyword(s):

Animal Model ◽

Femoral Head ◽

Bone Loss ◽

Postmenopausal Osteoporosis ◽

Bone Tissue ◽

Peripheral Blood ◽

List Type ◽

Mrna Levels ◽

Ovx Rats ◽

Anabolic Treatment

ABSTRACTMicroRNAs control the activity of a variety of genes that are pivotal to bone metabolism. Therefore, the clinical utility of miRNAs as biomarkers and drug targets for bone diseases certainly merits further investigation. This study describes the use of an animal model of postmenopausal osteoporosis to generate a comprehensive dataset on miRNA regulation in bone tissue and peripheral blood during bone loss and specifically anti-resorptive and osteo-anabolic treatment.Forty-two Sprague-Dawley rats were randomized to SHAM surgery (n=10) or ovariectomy (OVX, n=32). Eight weeks after surgery, OVX animals were further randomized to anti-resorptive treatment with zoledronate (n=11), osteo-anabolic treatment with teriparatide (n=11), or vehicle treatment (n=10). After 12 weeks of treatment, bone and serum samples were used for microRNA analysis using next-generation sequencing (NGS), mRNA levels using RT-qPCR, and bone microarchitecture analysis using nanoCT.Ovariectomy resulted in loss of trabecular bone, which was fully rescued using osteo-anabolic treatment, and partially rescued using anti-resorptive treatment. NGS revealed that both, anti-resorptive and anabolic treatment had a significant impact on miRNA levels in bone tissue and serum: out of 426 detected miRNAs, 46 miRNAs were regulated by teriparatide treatment an d 10 by zoledronate treatment (p-adj. < 0.1). Interestingly, teriparatide and zoledronate treatment were able to revert miRNA changes in tissue and serum of untreated OVX animals, such as the up-regulation of miR-203a-3p, a known osteo-inhibitory miRNA. We confirmed previously established mechanisms of miR-203a by analyzing its direct target Dlx5 in femoral head.Our data reveal a significant effect of ovariectomy-induced bone loss, as well as the two major types of anti-osteoporotic treatment on miRNA transcription in femoral head tissue. These changes are associated with altered activity of target genes relevant to bone formation, such as Dlx5. The observed effects of bone loss and treatment response on miRNA levels in bone are also reflected in the peripheral blood, suggesting the possibility of minimally-invasive monitoring of bone-derived miRNAs using liquid biopsies.HighlightsmicroRNA expression in bone tissue is altered by osteo-anabolic and anti-resorptive therapy in OVX rats.microRNA changes in untreated OVX rats are reverted by anti-osteoporotic therapy.miR-203a is up-regulated during bone loss and down-regulated following therapy.Bone tissue and serum levels of miR-203a are highly correlated.

Download Full-text